First-Quarter 2014 Business Review

• Sales:
  
  • Up 7.9%, including BioFire and at constant exchange rates
  • Up 4.1% like-for-like*, in line with the target for the year
    
    • Continued stabilization in Western Europe, up 1.4%*
    • Sustained solid growth in North America, up 5.4%*
  • Up 3.3%,  on a reported basis
• 2014 objective of 3 - 5% organic sales growth maintained
• Integration of BioFire effectively underway

Alexandre Mérieux, Chief Executive Officer, said: “During the first quarter of 2014, bioMérieux's sales rose by 4.1% at constant exchange rates and scope of consolidation, in line with our target for the year, and by 7.9% after consolidating the sales from BioFire, acquired in mid-January 2014. Sales continued to trend upwards in Europe and North America. BioFire’s FilmArray® system pursued its rapid expansion, with 55 new instruments installed since the company’s acquisition. In addition, we continued to roll out VIDAS® 3, whose application for approval was filed with Chinese authorities, and we prepared for the forthcoming market launch of our innovative new clinical microbiology platforms. Lastly, in line with our strategic plan, we are deploying a new operating organization designed to effectively meet public health challenges and our customers' needs around the world”.

* Like-for-like: on an organic basis (at constant exchange rates and scope of consolidation)